Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

NCT05954897 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC

Sponsor

Guangdong Provincial People's Hospital